VAV3 in human cancers: Mechanism and clinical implication

doi:10.1016/j.prp.2023.154681

Review

. 2023 Aug:248:154681.

doi: 10.1016/j.prp.2023.154681. Epub 2023 Jul 13.

VAV3 in human cancers: Mechanism and clinical implication

Affiliations

¹ Departemnt of Business Administration, Business School, Al-Bayt University, P.O.BOX 130040, Mafraq 25113, Jordan.
² College of Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna 66002, Iraq.
³ Institute of Pharmaceutical Research, GLA University, District-Mathura, U.P., 281406, India.
⁴ Department of Pharmaceutics and Pharmaceutical Technology, Taif University, Taif 21944, Saudi Arabia.
⁵ Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
⁶ Department of Engineering Graphics and Design Theory, Tashkent Institute of Irrigation and Agricultural Mechanization Engineers, National Research University, Tashkent, Uzbekistan.
⁷ College of Dentistry, Al-Ayen University, Thi-Qar, Iraq ‏.
⁸ Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq.
⁹ Medical Technical College, Al-Farahidi University, Baghdad, Iraq.
¹⁰ Biochemistry Department, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Rhoseinifard@razi.tums.ac.ir.

PMID: 37467637
DOI: 10.1016/j.prp.2023.154681

Review

VAV3 in human cancers: Mechanism and clinical implication

Sulieman Ibraheem Shelash Al-Hawary et al. Pathol Res Pract. 2023 Aug.

. 2023 Aug:248:154681.

doi: 10.1016/j.prp.2023.154681. Epub 2023 Jul 13.

Affiliations

¹ Departemnt of Business Administration, Business School, Al-Bayt University, P.O.BOX 130040, Mafraq 25113, Jordan.
² College of Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna 66002, Iraq.
³ Institute of Pharmaceutical Research, GLA University, District-Mathura, U.P., 281406, India.
⁴ Department of Pharmaceutics and Pharmaceutical Technology, Taif University, Taif 21944, Saudi Arabia.
⁵ Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
⁶ Department of Engineering Graphics and Design Theory, Tashkent Institute of Irrigation and Agricultural Mechanization Engineers, National Research University, Tashkent, Uzbekistan.
⁷ College of Dentistry, Al-Ayen University, Thi-Qar, Iraq ‏.
⁸ Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq.
⁹ Medical Technical College, Al-Farahidi University, Baghdad, Iraq.
¹⁰ Biochemistry Department, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Rhoseinifard@razi.tums.ac.ir.

PMID: 37467637
DOI: 10.1016/j.prp.2023.154681

Abstract

Guanine nucleotide exchange factors (GEFs) are primarily involved in signal transmission between cell membrane receptors and intracellular mediators. Upon replacing GDP with GTP, GEFs can alter their conformation, resulting in their binding to downstream effectors, such as GTPases like Ras homologous (Rho). VAV GEF family are versatile proteins working as an adaptor mediator and GEF for Rho GTPase. They act as a phosphorylation-dependent molecular switcher, fluctuating between active (tyrosine phosphorylated) and inactive (non-phosphorylated) conformation in cell signaling. Accumulating data showed that VAV3 is implicated in cancer progression. The higher levels of VAV3 in human cancers proposed that it may have an oncogenic role in cancer progression. Available studies demonstrated that VAV3 promoted cell proliferation, epithelial-mesenchymal transition (EMT), colony formation, cell cycle, survival, migration and invasion, and suppressed cell apoptosis. In addition, other studies indicated that VAV3 may have a prognostic value in cancer as well as it may act as a mediator in cancer chemoresistance. Here, we aimed to investigate the underlying molecular mechanism of VAV3 in cancer progression as well as to review its value as a prognostic biomarker and chemoresistance mediator in human cancers.

Keywords: Biomarker; Cancer; GEF; VAV3.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare they have no conflict of interests.

Cited by

Targeting guanine nucleotide exchange factors for novel cancer drug discovery.
Bannoura SF, Khan HY, Uddin MH, Mohammad RM, Pasche BC, Azmi AS. Bannoura SF, et al. Expert Opin Drug Discov. 2024 Aug;19(8):949-959. doi: 10.1080/17460441.2024.2368242. Epub 2024 Jun 17. Expert Opin Drug Discov. 2024. PMID: 38884380 Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

VAV3 in human cancers: Mechanism and clinical implication

Affiliations

VAV3 in human cancers: Mechanism and clinical implication

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Miscellaneous